Galvin Roy 4
4 · HAEMONETICS CORP · Filed May 17, 2023
Insider Transaction Report
Form 4
Galvin Roy
EVP, Chief Commercial Officer
Transactions
- Award
Non-qualified Stock Option (Right to Buy)
2023-05-15+5,068→ 5,068 totalExercise: $89.16Exp: 2030-05-15→ Common Stock (5,068 underlying) - Award
Common Stock
2023-05-15+2,243→ 4,689 total
Footnotes (4)
- [F1]The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
- [F2]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- [F3]This number includes unvested RSUs previously reported as well as 64 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023.
- [F4]Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.